NasdaqGS - Nasdaq Real Time Price USD

Tyra Biosciences, Inc. (TYRA)

10.43

+0.10

+(0.97%)

At close: June 13 at 4:00:01 PM EDT

10.43

0.00

(0.00%)

After hours: June 13 at 4:04:15 PM EDT

Tyra Biosciences to Participate at Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences:

PR Newswire last month

TYRA
+0.97%
One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

From what we can see, insiders were net buyers in Tyra Biosciences, Inc.'s ( NASDAQ:TYRA ) during the past 12 months...

Simply Wall St. last month

TYRA
+0.97%
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.

PR Newswire last month

TYRA
+0.97%
Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 2 months ago

TYRA
+0.97%
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.

PR Newswire 2 months ago

TYRA
+0.97%
Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

PR Newswire 3 months ago

TYRA
+0.97%
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer

PR Newswire 4 months ago

TYRA
+0.97%
Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33%

Key Insights Significant control over Tyra Biosciences by private equity firms implies that the general public has more...

Simply Wall St. 4 months ago

TYRA
+0.97%
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA.

PR Newswire 4 months ago

TYRA
+0.97%
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR N

PR Newswire 4 months ago

TYRA
+0.97%
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate

Key Insights Tyra Biosciences' estimated fair value is US$27.38 based on 2 Stage Free Cash Flow to Equity Tyra...

Simply Wall St. 6 months ago

TYRA
+0.97%
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2024, and highlighted recent corporate progress.

PR Newswire 7 months ago

TYRA
+0.97%
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares

Investors who take an interest in Tyra Biosciences, Inc. ( NASDAQ:TYRA ) should definitely note that the Chief...

Simply Wall St. 7 months ago

TYRA
+0.97%
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301).

PR Newswire 7 months ago

TYRA
+0.97%
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study. These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Tar

PR Newswire 7 months ago

TYRA
+0.97%
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentati

PR Newswire 7 months ago

TYRA
+0.97%
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 7 months ago

TYRA
+0.97%
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company’s initial focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions. The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most common form

Benzinga 7 months ago

TYRA
+0.97%

JNJ
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc

On October 10, 2024, Boxer Capital, LLC made a significant addition to its investment portfolio by acquiring 85,939 shares of Tyra Biosciences Inc (NASDAQ:TYRA). This transaction has increased the firm's total holdings in the company to 6,534,298 shares, reflecting a substantial commitment to Tyra Biosciences as a key component of its investment strategy. The firm is renowned for its strategic investments in innovative biotech entities, leveraging a deep understanding of the sector to identify and capitalize on emerging opportunities.

GuruFocus.com 7 months ago

TYRA
+0.97%
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for presentation, including a late-breaking oral presentation, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, in Barcelona, Spain.

PR Newswire 7 months ago

TYRA
+0.97%

Performance Overview

Return	TYRA	S&P 500 (^GSPC)
YTD	-24.96%	+1.62%
1-Year	-47.46%	+10.00%
3-Year	+93.87%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences to Participate at Upcoming Investor Conferences

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33%

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Performance Overview